menu
    • menu

    Company profile for Estrella Biopharma

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. It focuses to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer. The company is based in Emeryville, California.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Estrella BiopharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5858 Horton Street Suite 170 Emeryville, California, 94608
    Telephone
    Telephone
    (510) 318-9098
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.estrellabio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CGT Asia

    Not Confirmed

    envelop Contact Supplier

    CGT Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Estrella Immunopharma Gets $12/Share Coverage From Zacks Research
    Estrella Immunopharma Gets $12/Share Coverage From Zacks Research

    23 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260323976031/en/Estrella-Immunopharma-Inc.-NASDAQ-ESLA-Receives-Initiating-Coverage-with-a-Valuation-of-%2412.00Share-from-Zacks-Small-Cap-Research

    BUSINESSWIRE
    23 Mar 2026
    Share Share
    Estrella Immunopharma Presents Phase 1 STARLIGHT-1 Data On EB103
    Estrella Immunopharma Presents Phase 1 STARLIGHT-1 Data On EB103

    03 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260203345659/en/Estrella-Immunopharma-Announces-Late-Breaking-Oral-Presentation-of-Phase-1-STARLIGHT-1-Data-for-EB103-at-the-2026-Tandem-Meetings-of-ASTCT-CIBMTR

    BUSINESSWIRE
    03 Feb 2026
    Share Share
    Estrella Immunopharma Closes $8M Private Placement
    Estrella Immunopharma Closes $8M Private Placement

    06 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260106009556/en/Estrella-Immunopharma-Announces-Closing-of-%248.0-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement

    BUSINESSWIRE
    06 Jan 2026
    Share Share
    Estrella Immunopharma Announces $8M Private Placement
    Estrella Immunopharma Announces $8M Private Placement

    05 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260105244266/en/Estrella-Immunopharma-Inc.-Announces-%248.0-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules

    BUSINESSWIRE
    05 Jan 2026
    Share Share
    Estrella Advances STARLIGHT-1 to Phase II After DSMB Review
    Estrella Advances STARLIGHT-1 to Phase II After DSMB Review

    04 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251204012425/en/Estrella-Advances-STARLIGHT-1-Trial-into-Phase-II-Following-Positive-DSMB-Recommendation

    BUSINESSWIRE
    04 Dec 2025
    Share Share
    Estrella Immunopharma Finishes Second Dose Cohort In STARLIGHT-1
    Estrella Immunopharma Finishes Second Dose Cohort In STARLIGHT-1

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251030827975/en/Estrella-Immunopharma-Completes-Second-Dose-Cohort-in-STARLIGHT-1-Trial-of-EB103-with-Complete-Responses-in-All-Evaluable-Patients

    BUSINESSWIRE
    03 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search